当前位置： SCI文献检索 > ANNALS OF HEMATOLOGY期刊下所有文献 > Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Abstract：

:Several revisions of International Prognostic Index (IPI) have been proposed for patients with diffuse large B-cell lymphoma (DLBCL) after the introduction of rituximab. Expanding evidence suggests that baseline absolute lymphocyte count (ALC) is also an independent factor for outcome prediction. We investigated the optimal prognostic model for these patients in the rituximab era. The study enrolled 274 consecutive patients with DLBCL receiving first-line cyclophosphamide, doxorubicin, vincristine, and prednisone based chemotherapy with rituximab between 2003 and 2009. Five factors within IPI and ALC were entered for Cox regression analysis. Overall survival (OS) and progression-free survival were calculated for different risk groups of models. Efficacy of models was compared by the value of Akaike information criterion (AIC). Revised IPI (R-IPI) and ALC/R-IPI, but not IPI, were informative to discriminate between different risk groups. In multivariate analysis for individual factors of the prognostic models, performance status >1 [odds ratio (OR) 3.59], Ann Arbor stage III or IV (OR 2.24), and ALC <1 × 10⁹/L (OR, 2.75) remained significant. Another modified score based on the three factors divided patients into four risk groups and the 3-year OS rate was 93, 77, 39, and 13 %, respectively. By comparing AIC values in the Cox proportional hazards model, the modified three-factor model was the superior prognostic model followed by established ALC/R-IPI, R-IPI, and standard IPI. In conclusion, the addition of the novel factor, ALC, interacts with other established factors in outcome prediction for DLBCL. Development of a new score is needed for a better risk stratification in the rituximab era and would be helpful in the design of future clinical trials. The proposed three-factor model should be validated in large-scale studies.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Huang YC,Liu CY,Lu HJ,Liu HT,Hung MH,Hong YC,Hsiao LT,Gau JP,Liu JH,Hsu HC,Chiou TJ,Chen PM,Tzeng CH,Yu YB

doi

10.1007/s00277-013-1807-0

subject

Has Abstract

pub_date

2013-11-01 00:00:00

pages

1513-20

issue

eissn

0939-5555

issn

1432-0584

journal_volume

pub_type

杂志文章

在线工具

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.